Results 31 to 40 of about 52,225 (202)

Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]

Journal of Lipid Research, 2013
Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns, Marimuthu Subathra, Paola Signorelli, Young Choi, Xiaofeng Yang, Yong Wang, Maristella Villani, Kapil Bhalla, Daohong Zhou, Chiara Luberto   +9 more
doaj   +1 more source

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. [PDF]

PLoS ONE, 2013
Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies.
Octavian Bucur, Andreea Lucia Stancu, Ioana Goganau, Stefana Maria Petrescu, Bodvael Pennarun, Thierry Bertomeu, Rajan Dewar, Roya Khosravi-Far   +7 more
doaj   +1 more source

Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia

Advanced Science, 2022
The Bcr/Abl plays a central role in Philadelphia chromosome‐positive (Ph+) leukemia because of the constitutively activated Abl tyrosine kinase and its downstream pathways.
Bohan Ma, Hui Feng, Chao Feng, Yi Liu, Hailing Zhang, Jincheng Wang, Wenjuan Wang, Pengcheng He, Fan Niu   +8 more
doaj   +1 more source

Association of Myeloid Aberrant Antigens and the Presence of BCR-ABL Gene Re-arrangements in ALL Patients

Haematology Journal of Bangladesh, 2020
Background: BCR-ABL translocation is the most common genetic abnormality associated with adult Acute Lymphoblastic Leukaemia (ALL) with poor outcome. Objective: The aim of the study was to determine the association of myeloid aberrant antigens and the ...
Md. Shafiul Azam, Khaza Amirul Islam, Sharmin Mafruha, Mirza Golam Sarwar, Md. Salahuddin Shah, Md. Abdul Aziz   +5 more
doaj   +1 more source

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib

Blood Cancer Journal, 2015
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
A. Zhou, E. Knoche, E. Engle, Daniel A. C. Fisher, S. Oh   +4 more
semanticscholar   +1 more source

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

Haematologica, 2008
Treatment with imatinib is very effective in Bcr-Abl positive leukemia. However, development of resistance to this drug is a common phenomenon in late stage disease.
Rama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S. Götze, Justus Duyster   +5 more
doaj   +1 more source

DNA vaccination against bcr-abl-positive cells in mice

International Journal of Oncology, 2009
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12B1, which both expressed p210bcr-abl and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system.
Vincent, Lucansky, Eva, Sobotkova, Ruth, Tachezy, Martina, Duskova, Vladimir, Vonka   +4 more
openaire   +3 more sources

Imatinib spells BAD news for Bcr/abl-positive leukemias [PDF]

Proceedings of the National Academy of Sciences, 2006
One of the medical success stories of the past decade has been the development of new agents to treat chronic myelogenous leukemia (CML). Building on earlier studies that identified the t(9;22) chromosomal translocation in CML, cloned the BCR/ABL fusion gene, and demonstrated the ability of the resulting kinase to transform cells, investigators ...
openaire   +2 more sources

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

BMC Cancer, 2012
Background Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Mian Afsar, Metodieva Anna, Badura Susanne, Khateb Mamduh, Ruimi Nili, Najajreh Yousef, Ottmann Oliver, Mahajna Jamal, Ruthardt Martin   +8 more
doaj   +1 more source

Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress

Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, 2015
BCR-ABL positive (+) acute lymphoblastic leukemia (ALL) accounts for ~30% of cases of ALL. We recently demonstrated that 2-deoxy-D-glucose (2-DG), a dual energy (glycolysis inhibition) and ER-stress (N-linked-glycosylation inhibition) inducer, leads to ...
Guy J Leclerc, J. DeSalvo, Jianfeng Du, Ningguo Gao, Gilles M. Leclerc, M. Lehrman, T. Lampidis, J. Barredo   +7 more
semanticscholar   +1 more source